@theneaptide.comBiossil just raised $153M to find value in drug candidates that failed — not because the molecule was wrong, but because the trial design was.
There's a version of that story in CEA.
The science is proven. The commercialization model is what's still catching up.
@theneaptide.comArlene Dickinson just put $150M behind the argument she's been making all year.
Velocity Agri-Capital. $25-50M equity investments. Canadian processors, producers, manufacturers, growers.
Food sovereignty isn't just a slogan anymore. It's a term sheet.